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Abstract
Background: The raising prevalence of type-2 diabetes mellitus and obesity has been recognized as a major problem
for public health, affecting both developed and developing countries. Impaired fasting plasma glucose has been previously
associated with endothelial dysfunction, higher levels of inflammatory markers and increased risk of developing insulin
resistance and cardiovascular events. Besides life-style changes, the blockade of the renin-angiotensin system has been
proposed as a useful alternative intervention to improve insulin resistance and decrease the number of new type-2
diabetes cases. The aim of this clinical trial is to study the effect of the treatment with Candesartan, an angiotensin II
receptor antagonist, on the insulin resistance, the plasma levels of adipoquines, oxidative stress and prothrombotic
markers, in a group of non diabetic, non hypertensive, dysglycemic and obese subjects.
Methods and design: A randomized, double blind, cross-over, placebo-controlled, clinical trial was designed to assess
the effects of Candesartan (up to 32 mg/day during 6 months) on the Homeostasis Model Assessment (HOMA) index,
lipid profile, protrombotic state, oxidative stress and plasma levels of inflammatory markers. The participants will be
recruited in the "Fundación Cardiovascular de Colombia". Subjects who fullfil selection criteria will receive permanent
educational, nutritional and exercise support during their participation in the study. After a 15 days-run-in period with
placebo and life-style recommendations, the patients who have a treatment compliance equal or greater than 80% will
be randomlly assigned to one of the treatment groups. Group A will receive Candesartan during 6 months and placebo
during 6 months. Group B will receive placebo during the first 6 months, and then, Candesartan during the last 6 months.
Control visits will be programed monthly and all parameters of interest will be evaluated every 6 months.
Hypothesis: Treatment with Candesartan, could improve the HOMA index, the response to the oral glucose tolerance
test and reduce the plasma levels of adipoquines, oxidative stress and prothrombotic markers, in non diabetic, non
hypertense subjects with dysglycemia and abdominal obesity, recruited from a population at high risk of developing insulin
resistance. These effects are independent of the changes in arterial blood pressure. Trial registration: NCT00319202
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Background
During the second half of the 20th century the prevalence
of type-2 diabetes mellitus (DM2) has increased dramati-
cally all over the world [1]. It has been estimated that
more than 171 million people suffer from this disease and
that this number could increase to 366 million by 2030,
of which 298 million would be from developing countries
[2]. Currently, in Latin America, the DM2 prevalence
ranges from 1.2% to 8%, and it is expected to increase to
38% during the next 10 years [3]. This epidemic has been
related with the growing prevalence of obesity, especially
abdominal [4]. Recently, we have demonstrated that the
presence of cardiovascular risk factors in the Andean pop-
ulation is associated with a lower cut-off point of waist cir-
cumference [5,6] than the one used for Caucasian
populations [7]. We have previously described that
Andean population with pathologies like metabolic syn-
drome, hypertension and preeclampsia, all of them asso-
ciated with an increased risk of cardiovascular diseases
(CVD), presents higher plasma levels of inflammatory
markers such as C-reactive protein (CRP) and proinflam-
matory cytokines [8-11].
Patients with DM2 have an increased risk of developing
coronary artery disease by 2 to 4 fold and a higher risk of
presenting recurrent and/or mortal cardiovascular events
by 1.5 to 3 fold [12]. Based on the risk of developing
micro-vascular complications, the American Association
of Diabetes (ADA) reduced the threshold for DM2 to a
fasting glucose level ≥126 mg/dl [13]. Moreover, the crite-
ria of impaired fasting glucose (IFG) was defined as fast-
ing glucose plasma level between ≥ 100 mg/dL and <126
mg/dL, and was proposed as equivalent to the impaired
glucose tolerance (IGT) category obtained by oral glucose
tolerance test (OGTT) [13]. Several articles have shown
that patients with IFG have an increased risk of cardiovas-
cular morbidity and mortality [14,15]. This association
has been explained by the participation of hyperglycemia,
especially postprandial, in the development of atheroscle-
rosis due to metabolic and structural changes of the vascu-
lar wall [16]. In the long term, this condition may result
in macrovascular alterations and in the increased risk of
CVD [15]. According to these observations, our group has
recently showed that patients with IFG, regardless of other
traditional cardiovascular risk factors, presented a higher
risk of luminal coronary disease [17].
The etiological factors of DM2 have not been totally eluci-
dated, but it is well known that insulin resistance precedes
the DM2 onset by 10 to 20 years [18,19]. Individuals with
insulin resistance have impaired endothelium-dependent
vasodilation and a loss of the physiological vasodilation
caused by insulin [20], which is primarily due to an
increased expression of the endothelial nitric oxide syn-
thase (eNOS) [21]. It is also well known that obesity,
hypercholesterolemia and diabetes are related to a reduc-
tion in flow-mediated dilation (FMD) [22,23], which is
mainly caused by the endothelial production of nitric
oxide (NO).
Endothelial dysfunction is a condition defined as a
decrease in the production of NO and the predominance
of vasoconstrictor substances that result in an increase of
the the vascular tone that predisposes to a prothrombotic
and proatherogenic state [24,25].
Intra-abdominal adipocytes are directly related to hyper-
insulinemia and insulin resistance [26]. Hyperinsuline-
mia promotes the release of free fatty acids (FFA) from the
adipocytes and their hepatic transformation into oxidized
LDL, which has a higher atherogenic potential. Moreover,
abdominal adipocytes are an important source of proin-
flammatory cytokines, such as tumor necrosis factor alpha
(TNF-α) and interleukin 6 (IL-6) [27], that can reduce the
expression and activity of the eNOS in human cultivated
umbilical endothelium cells [28] which suggests that this
could be one of the mechanisms by which abdominal
obesity is related to endothelial dysfunction [29]. Further-
more, we have recently demonstrated that in cultured
human endothelial cells, angiotensin II (AII), through its
type 1 receptor (AT1), stimulates the TNF-α production
which increases the activity of matrix metalloproteinase-2
(MMP-2)[30], enzyme that affects the endothelium struc-
ture as well as the stability of the atherosclerotic plaque
[31] (Figure 1).
All of them, angiotensin receptors (AT1 and AT2 types),
angiotensin converting enzyme (ACE) and angiotensino-
gen, are widely expressed in the human adipose tissue
[32,33]. Furthermore, the angiotensinogen gene expres-
sion is directly related to the degree of abdominal obesity
[34]. Moreover, a direct correlation between body mass
index and the circulating levels of angiotensinogen and
AII has been reported [35]. These results demonstrate that
the visceral adipocyte is both, a generator and a target tis-
sue of the AII through the activation of AT1 and AT2 recep-
tors. AII has regulatory functions in the adipogenesis and
the size of the fat reservoir. Experiments in vitro have
shown that AII indirectly induces the transformation of
adipocytes precursor cells into mature fat cells [36], sug-
gesting that this is one of the mechanisms by which AII
stimulates the accumulation of the adipose tissue. In stud-
ies realized in rodents, the treatment with AII Receptor
Blockers (ARBs), caused a reduction in the weight and in
the size of the adipocytes independently of the food
intake [37]. It is normally accepted that AT2 receptors are
the most commonly and widely distributed receptors of
AII, however, effects of AII mediated by AT1 receptors on
the storage of triglycerides and on the activity of key lipo-
genic enzymes such as fatty acid synthase (FAS) and glyc-Trials 2006, 7:28 http://www.trialsjournal.com/content/7/1/28
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erol-2 dehydrogenate phosphate (GDPH) have also been
demonstrated in cultured cells [38].
The increase in the production and storage of FFA induces
insulin resistance through the inhibition of the transpor-
tation and phosphorylation of glucose in skeletal muscle,
which produces a reduction of the glycogen synthesis and
glucose oxidation rates [39]. Additionally, it has been sug-
gested that FFA interfere with the stimulation of the
expression of the glucose transporter GLUT-4 and the hex-
okinase activity [39]. AII and insulin share signal trans-
duction pathways. Thus, insulin activates proteinkinase C
title Figure 1
title. Physiopathological mechanisms relating abdominal adiposity, angiotensin II, insulin resistance and cardiovascular events. 
For description see text.Foot note.FFA: Free Fatty Acids, FAS:, GDPH:, IL-6: Interleukine 6, IL1β: Interleukine 1β, 
TNFα: Tumoral Necrosis Factor α, AI: Angiotensin I, AII: Angiotensin II, ACE: Angiotensin Converting Enzime, eNOS: 
endothelial Nitric Oxide Sintase, CPKII: Creatinphosphokinase-II, IRS-1: Type 1 Insulin Soluble Receptor IRS-2: Tipe 2 Insu-
lin Soluble Receptor, GLUT-4:Type 4 Glucose Membrane Trasnporter, MMP2: Matrix Metalloproteinase-2, NO: Nitric 
Oxide, UPC-2: Uncoupling Portein 2, PPARs: Peroxisome Proliferator-Activated Receptors, DM2: Tipe 2 Diabetes Mellitus, 
CVE: Cardiovascular Events, scater line: Inhibition or delay, filled line: Activation or increment.Trials 2006, 7:28 http://www.trialsjournal.com/content/7/1/28
Page 4 of 12
(page number not for citation purposes)
(PKC) through the tyrosine phosphorilation of insulin
receptor substrate type 1 and 2 (IRS-1 and IRS-2) and
stimulates the MAP-kinase pathway signaling, whereas
the AII inhibits PKC that alters the intracellular signaling
of insulin [40].
All also has a stimulating effect on the transcription rate of
the ob gene in human adipocytes, which codifies leptin,
inhibiting appetite and regulating thermogenesis [41].
The sustained increase in leptin levels leads to leptin-
resistance, moreover, high levels of leptin produce a
greater expression of the uncoupling protein 2 (UPC-2)
mediated by peroxisome proliferator-activated receptors
(PPARs). UPC-2 interferes with the mitochondrial respira-
tory chain of the pancreatic β-cells, reducing the ATP gen-
eration and blocking the first peak of insulin secretion and
favoring the onset of hyperglycemia [42]. Contrary to the
results obtained in in vitro experiments [43], the infusion
of AII to animals causes no effect over leptine expression
[44]. This contradictory result could be explained by the
activation of the sympathetic nervous system, which
impedes the stimulating effect of AII on leptin produc-
tion. Furthermore, high concentrations of leptin increase
blood pressure, through sympathetic nervous activation
and the sodium retention in the kidneys contributing to
the development of hypertension in obese subjects [45].
The administration of ARBs in animal models, increase
adiponectin plasma levels [46], which stimulate glucose
utilisation and fatty-acid oxidation by activation of AMP-
kinase [47]. In fact, the administration of Candesartan, an
antagonist of AT1 receptor, to a group of hypertense sub-
jects caused a reduction of adiponectin, C-reactive protein
and markers of insulin resistance, such as the QUICKI
index [48]. Furthermore, TNFα, another proinflammma-
tory cytokine, down-regulates the expression of adiponec-
tin gene, impairs signal transduction of insulin in muscles
[49] and it is proposed as a factor involved in the etiology
of obesity related insulin resistance syndrome.
All acts also as a pro-oxidant substance by regulating the
activity of the enzyme NADPH oxidase that catalyzes the
production of reactive oxygen species (ROS), such as the
superoxide anion and peroxynitrite[50]. ROS are sub-
stances that are directly related to the development of
atherosclerotic plaque not only by inactivating NO but
also by increasing the expression of cellular adhesion
molecules that favor the migration of monocytes and leu-
kocytes to the vascular wall [51] and by stimulating the
growth, the remodeling and the migration of smooth
muscle cells [52]. Moreover, AII has a procoagulant effect
by stimulating the production of Plasminogen Activator
Inhibitor-1 (PAI-1) [53], which is the principal endog-
enous inhibitor of fibrinolysis "in vivo" and is associated
with atherosclerosis [54].
The treatment with ACE inhibitors (ACEIs) and ARBs has
been shown to improve the peripheral insulin resistance
in both, animal [55] and clinical models [56]. The mech-
anism by which the renin-angiotensin-aldosterone system
(RAS) blockade has a beneficial effect on the responsive-
ness to insulin has not been totally clarified. Some
changes in peripheral insulin sensitivity after treatment
with ACEIs or ARBs might be partially mediated by
changes in local blood flow to sites of glucose uptake [57].
However, a variety of non-haemodinamic effects have
also been reported. In obese Zucker-type rats, it was dem-
onstrated that the chronic administration of a selective
ARBs produced a significant increase in the GLUT-4
expression in skeletal muscle, a reduction in the concen-
trations of plasma fatty acids and an improvement in the
responsiveness to insulin [58]. Moreover AII also
increases the expression of Hexokinase, a key enzyme in
glucose metabolism of skeletal muscle [59].
ARBs have also been associated with an increase of the
PPARγ activity [60] which plays an important role in the
regulation of insulin action, by controlling the transcrip-
tion of multiple genes involved in the metabolism of lip-
ids and glucose [61]. Even in absence of AT1 receptors,
ARBs were shown to promote the activation of PPARγ in
human adipose cells, which supports the existence of
additional mechanisms by which ARBs improve the
responsiveness to insulin [61,62].
Some clinical trials have demonstrated that ACEI and
ARBs reduce the number of new-onsets DM2 when com-
pared with other anti-hypertensive therapies [63,64]. In
the study SCOPE [65] the use of Candesartan as an antihi-
pertensive treatment, was associated with a relative reduc-
tion in new-onset diabetes by 19% (95% IC- 2 to 42%, p
= 0.09) during a mean follow-up period of 3.7 years. This
result is consistent with observations in other studies
using blockers of the RAS in subjects with hypertension
[66] including the LIFE study that compared Losartan and
atenolol [67], the ALPINE study that compared Cande-
sartan and hydroclorotiazide HCT [68], and the VALUE
study that compared Amlodipine and Valsartan[63].
Moreover, results from studies conducted in normotense
subjects, like the CHARM study [69], in which ARBs,
caused a reduction in new-onsets DM2, suggest that the
observed effects of these medications over the develop-
ment of DM2 are independent of their effects over blood
pressure. However, to this day, we lack results from clini-
cal trials aimed specifically at describing the effects of the
ARBs over dysglicemia/IGT in normotense non diabetic
and obese subjects.
Although the mechanisms are still speculative, the results
discussed above suggest that AII produced in the adi-
pocytes of subjects with abdominal obesity is associatedTrials 2006, 7:28 http://www.trialsjournal.com/content/7/1/28
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with insulin resistance syndrome and dysglycemia, and
support the conduction of clinical trials oriented to dem-
onstrate the beneficial effect of ARBs in the insulin sensi-
tivity of individuals at high risk of developing CVD and
DM2.
Hypothesis
Candesartan (32 mg/day during 6 months) has a benefi-
cial effect on fasting plasma glucose, proinflammmatory,
prothrombotic and oxidative stress markers in non dia-
betic, non hypertense subjects, with dysglicemia and
abdominal obesity. The improvement of these markers is
independent of changes in arterial blood pressure.
Methods/design
General objective
To evaluate the effect of Candesartan 32 mg/d during 6
months on the sensibility to insulin, the concentration of
inflammatory adipoquines and the prothrombotic and
oxidative stress markers in non diabetic, non hypertense
subjects with dysglycemia and abdominal obesity,
recruited from a population with high risk of developing
metabolic syndrome and insulin resistance.
Specific objectives
▪ To establish the effect of the administration of Cande-
sartan on the insulin resistance assessed through the
HOMA index, fasting plasma glucose, OGTT, and HbA1c
levels.
▪ To study the effect of Candesartan 32 mg/d adminis-
trated during 6 months on fasting plasma levels of adipo-
quines such as leptin, resistin, adiponectin, IL-6 and CRP.
▪ To evaluate the effect of Candesartan on prothrombotic
markers, such as D dimer, tPA/PAI-1 ratio.
▪ To determine whether the administration of Cande-
sartan decreases the concentration of oxidative stress
markers such as plasma oxidized/reduced glutathione
ratio, total oxidative capability, malonaldehyde and uri-
nary 8-Isoprostanes.
▪ To determine whether the effects of Candesartan on the
insulin sensibility, adipoquines and oxidative stress, are
independent of its effect upon the blood pressure.
Study design
Randomized, double blind, placebo-controlled, cross-
over clinical trial (Figure 2).
Study treatments
▪ Treatment A: Candesartan 16 mg (one tablet per day)
taken with breakfast during 4 weeks and then increased to
the optimal dose of 32 mg/d (two tablets) during the next
20 weeks, depending on the subjects' tolerance.
▪ Treatment B: Placebo tablets administered similarly to
treatment A, one tablet daily during 4 weeks and then 2
tablets per day during the next 20 weeks.
All the subjects will be included in a therapeutic life-style
change program (TLC: educational, nutritional and exer-
cise support) during the study.
Study groups
The study embraces two arms (Figure 2):
▪ Group 1: will receive the treatment A during the first 24
weeks and then the treatment B during the last 24 weeks.
▪ Group 2: will receive the treatment B during the first 24
weeks and then the treatment A during the last 24 weeks.
Population
Participants will be non diabetic non hypertense individ-
uals of both genders, older than 18 years with abdominal
obesity and dysglycemia and/or IGT. Inclusion and exclu-
sion criteria are shown in Table 1
Sample size
A sample size of 84 subjects was estimated, considering a
crossover clinical trial design as proposed by Hills and
Armitage [70], accepting a type I error of 0.05, a power of
90%, and assuming a difference of 20 % in the HOMA
index after 6 months of treatment with Candesartan (3 to
2.4) and a maximum standard deviation of 1.5. The final
size of the sample, adjusted for a drop-out of 8%, is 100
subjects (50 in each group). The sample size ensures a
power of 90% to detect differences in fasting glycemia of
at least 8 mg/dL (0.44 mMol/L) with a standard deviation
(SD) of 20 mg/dL (1.1 mMol/L), or a difference of 14 mg/
dL (0.77 mMol/L) in the 2 hours post load glycemia with
a SD of 40 mg/dl (2.2 mMol/L).
Procedures
Enrollment
This study will be realized in an adult population with a
maximum enrollment period of one year. Screening visit
will include a semi-structured interview, anthropometry
and blood pressure evaluation. Eligible subjects will be
scheduled one week later for "Visit A", to perform a new
interview, a physical examination and to withdraw blood
samples, after a 10 hour fasting period, to determine
plasma glucose levels, lipid profile, hepatic and kidney
function and OGTT. Those who fulfill screening criteria
will be included in a run-in phase to receive placebo and
the standard treatment with TLC. The patients will be
blinded during this phase, which will last 2 weeks. TheTrials 2006, 7:28 http://www.trialsjournal.com/content/7/1/28
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patients with a compliance equal or greater than 80% dur-
ing this "Run in" phase will be included in the study.
Baseline assessments
Visit B will include measurements of blood pressure,
anthropometric parameters, OGTT and electrocardio-
gram. A fasting blood sample and a 24 hour urine sample
will be taken and stored (-70°C) to determine glucose,
HbA1c, insulin, IL-6, leptin, resistin, adiponectin, tisular
plasminogen activator (tPA), PAI-1, oxidized/reduced glu-
tathione, malonaldehyde and 8-isoprostanes in urine.
Once the patient completes the foregoing steps, during
visit 1 he/she will be randomized to one of the arms of the
treatment. For this purpose, a randomization system by
blocks of 4 will be used. New tests will be performed at the
end of each treatment, according to the study flowchart
Table 1: Selection criteria
Inclusion criteria 
• Men and women older than 18 years of age.
• Waist circumference ≥ 90 cm in male and ≥ 80 cm in female.
• To have fasting plasma glucose between 100 and 125 mg/dL and/or OGTT at 2 hours ≥ 140 mg/dL and <200 mg mg/dL.
• Having a treatment compliance over 80% at the end of the run-in phase.
All women with bearing potential must have a secure contraceptive method. Secure method will be considered: surgical sterilization, 
postmenopause condition with an age greater than 45 years and a period of amenorrhea ≥ 2 years. (In premenopausal women, the use of hormonal 
method or two barrier contraceptive methods including 1 month after the conclusion of the active phase of study treatment).
Exclusion criteria
• Prior diagnosis of type 1 or 2 diabetes mellitus, chronic or acute renal insufficiency, coronary disease clinically evident (acute myocardial infarction, 
chest angina, myocardial revascularization) or cardiac insufficiency, or history of prior cardiovascular events (AMI, CVD, or CABG).
• Significant chronic disease (terminal stage cirrhosis or hepatic disease or cancer) that affects the survival of patients at 24 months.
• Chronic inflammatory diseases except obesity (lupus, rheumatoid arthritis, etc.).
• Blood arterial pressure >140/90.
• Acute infection of any etiology within 4 weeks prior to the beginning of the study.
• Use of steroid hormones or NSAIDs 4 weeks prior to the beginning of the study.
• Patient enrolled in a program or treatment to lose weight, 8 weeks prior to the study entry.
• Patient requiring treatment with immunosuppressive agents, for any circumstance.
• Patient who has participated in a clinical trial in the 8 weeks prior to the study entry.
• Patient who requires a major surgical procedure during the next 12 months, after enrollment (Abdominal or thoracic surgery, vascular, 
neurosurgery, urologic or gynecologic surgical procedure).
• Patient with history of severe chronic gastritis or any condition of the gastrointestinal tract that may affect the absorption and/or distribution of 
any drug administered orally.
• Alteration of the hepatic function tests.
• Triglycerides ≥ 600 mg%.
• Serum creatinin ≥ 1.5 mg/dl or calculated creatinin clearance (Cockroft's method) less than 50 ml/min.
• History of use of psychoactive drugs or abuse of alcohol.
• Positive pregnancy test in the screening visit.
• Concomitant treatment with any other antihypertensive drug.
• Contraindication to receive treatment with Candesartan.
• Pathological alterations of aortic or mitral cardiac valves (stenosis o insufficiency) or hypertrophy cardiomyopathy.
• Denial to sign informed consent, or any mental condition that makes the patient part of a susceptible population
title Figure 2
title. Study design.Trials 2006, 7:28 http://www.trialsjournal.com/content/7/1/28
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(Table 2). Randomization and preparation of medica-
tion/placebo will be done by AstraZeneca at Mölndal,
Sweden.
Active follow-up
Seven days after beginning the treatment, and every
month thereafter, the subjects will be asked to return for a
visit in order to verify compliance, evolution of blood
pressure and occurrence of adverse events. In the months
1 and 3 of each treatment, new fasting glucose determina-
tion will be done in all subjects. All basal measurements
will be repeated at the end of each treatment (every 6
months).
Passive follow-up
All the subjects will undergo a passive follow-up (tele-
phonic follow-up) 30 days after concluding the treatment.
Blood samples
In fasting conditions (at least 10 hours), blood samples
will be taken from the antecubital vein, with appropriate
conditions of asepsia and antisepsia, using 3 vacutainer
tubes, one dry, another with citrate, and the other con-
taining EDTA. After 10 minutes in vertical position, all
samples will be centrifugated at 3000 rpm during 15 min-
utes to extract the serum or plasma. Part of the samples
obtained during visits B, 5 and 9 will be stored in
Ependorf vials at -70°C until the end of the study.
Anthropometrical measurements
All anthropometrical measurements will be taken first
thing in the morning after urine elimination, with the
subject using light clothing and no shoes.
Weight: will be measured with the patient standing and
then registered after rounding it to the nearest 200 grams.
The weight scale will be calibrated to 0 before each meas-
urement.
Height: will be measured using a metric tape with the
patient standing against the wall in Frankfort's position,
Table 2: Study flowchart.
V i s i t S c r e e n i n g AB12345 6 7 1 a2 a3 a4 a5 a6 a7 a8 a
Week -4 -3 -1 0 1 4 8 12 16 20 24 25 28 32 36 40 44 48 52
Passive Follow up x
Nurse interview x x x x x x x xxxxxxxxxxx
MD interview xx x x x x x x x x x
Medication delivery x x x x xxxx xxxxx
Physical examination xx x x x x x x x x
Randomization x
Sample withdrawing xx x x x x x
Sample storage xx x
ECG x
Hemogram xx x
Plasma glycemia xx x x
Lipid Profile xx x
Hepatic Function test xx x
Renal Function test xx x
OGTT xx x
Insulin xx x
CRP xx x
IL-6 xx x
Hb A1c xx x
Leptin xx x
Resistin xx x
Adiponectin xx x
TPA xx x
PAI-1 xx x
8-Isoprostanes xx x
Malonaldehyde xx x
Oxi/Red Glutathione xx xTrials 2006, 7:28 http://www.trialsjournal.com/content/7/1/28
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and the value marked by a ruler placed horizontally on
the head of the patient.
Heart rate: number of beats per minute will be measured
in the radial artery.
Blood pressure: will be taken twice (with a difference of
5 minutes between the measurements) using a mercury
sphygmomanometer in 2 occasions on the right arm, with
the patient comfortably seated, after a 5 minute rest.
Systolic blood pressure (SBP) will be determined by the
first audible sound (Korotkoff phase 1). Diastolic blood
pressure (DBP) will be registered when the sound disap-
pears (Korotkoff phase 5). The patient should not have
smoked 30 minutes prior to the blood pressure measure-
ment. The pneumatic arm cuff must cover 2/3 of the
upperarm's length; its inferior border must be 2–3 cm
over the antecubital space; the cuff will be slowly deflated.
The mean blood pressure (MBP), will be calculated using
the following formula [SBP+(2*DBP)]/3
Waist circumference: will be measured in 2 occasions
with the patient in a standing position, with the arms on
the sides and using a measuring tape adhered to a
dynamometer that exerts a force of 750 gr. The measuring
tape will be placed horizontally in a middle point
between the iliac crest and the anterior costal border. The
difference between the two measurements should not be
more than 0.5 cm.
Hip circumference: will be measured in 2 occasions with
the patient in a standing position with the arms on the
sides of the body, using a measuring tape adhered to a
dynamometer that exerts a force of 750 gr. The hip cir-
cumference will be assessed over the major trochanters.
The difference between the two measurements should not
be more than 0.5 cm.
Waist-Hip Relation (W/H-R): will be obtained from the
ratio between the waist and hip circumferences.
Antero-posterior diameter: will be measured twice with
the patient in a decubitus supine position, using a ruler
perpendicular to the bed and registering the cutting point
with the tape applied horizontally on the abdomen. The
difference between the two measurements should not be
more than 0.5 cm.
Body Mass Index (BMI): This index will be estimated
using the weight in kilograms divided by the second
power of the height expressed in meters.
Biochemical markers
Routine clinical test and inflammation markers will be
processed in the Clinical Research Laboratory from the
"Fundación Cardiovascular de Colombia" (Floridablanca,
Colombia). The measurement of oxidative stress markers
will be processed in the laboratories of Complutense Uni-
versity (Madrid, Spain).
Glycemia, Lipid profile, Serum Creatinine, Hepatic
enzymes (AST/ALT) will be quantified by a routine color-
imetric method. (Biosystems BTS-303 Photometric,
España).
Glycosylated Hemoglobin A1c: Will be determined with
a quantitative automated technique GlycoHemoglobin
Analyzer (DCA 2000+ Bayer®.) using a whole blood sam-
ple.
Insulin, High-sensitivity C-Reactive Protein and Inter-
leukin 6: will be determined by high sensitivity chemolu-
minescent inmunoassay technique (IMMULITE ®
Automated Analyzer, Diagnostic Products Corporation,
Los Angeles, USA).
Leukocyte count and differential formula: will be deter-
mined by an automated counter (Baker System 9120 AX ®,
Biochem Inmunosystem, USA).
Glucose Tolerance Test: will be done after a fasting
period of at least 10 hours. After urine elimination, an
intravenous catheter will be placed in the antecubital vein
and blood samples will be withdrawn to assess the base-
line blood glucose, then, a glucose load equivalent to 75
gr diluted in 300 mL of water will be administered to each
study subject within a period of no more than 10 minutes.
Then, after 2 hours, a new blood sample will be with-
drawn to assess glycemia. Patients should not eat any-
thing or do any exercise during the test.
Serum Leptin, resistin and adiponectin: will be meas-
ured by ELISA technique.
HOMA Index: Will be obtained from a mathematical
model using the following formula:
Quality assurance systems
The inter- and intra-assay variation coefficient will be
determined for all measurements. In order to eliminate
the inter-assay error, all biochemical determinations will
be performed at once.
Data processing and quality assurance
All study data will be collected by trained personnel.
These data will be recorded on forms previously designed
HOMA
Glycemia mg dL Insulinemia mU mL
=
⎛
⎝
⎜
⎞
⎠
⎟∗ (/ )
.
(/ )
.
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for such purpose (Case Report Form-CRF). After complet-
ing the CRF, a monitor will review them to assure that
they are correctly filled and legible. All corrections will be
done by the monitor according to the Good Clinical Prac-
tice guidelines. Then, the information will be typed and
stored twice in independent data base. A computer pro-
gram (Epi-Info 2000) will be used to compare both data-
base. Every discrepancy will be printed and corrected
using the original CRF as reference.
Data monitoring
The study coordinator will make sure that data is ade-
quately collected. He/she will register the study visits and
the time of data collection and the different procedures, as
well as the compliance to the treatment.
Data management
The FCV Research Institute will be responsible for the data
management. Once the data is correctly recorded, the
means and ranges will be estimated and the relevant vari-
ables will be crossed to identify inconsistencies or extreme
values which could result from errors in data management
(internal consistency analysis). Any detected error will be
corrected using the original form and the lab reports as
references, maintaining the 2 original database
untouched.
Modifications and statistical procedures during the data
analysis will be documented in the Stata 9.0 program,
which will allow the replication of the data analysis when-
ever necessary.
Statistical analysis
The study is set forth as an efficacy study of Candesartan
in the improvement of the insulin sensibility and the
OGTT results. The averages and proportions with their
corresponding 95% confidence intervals will be obtained
in a descriptive analysis for all clinically relevant variables
measured during the baseline evaluation. In order to eval-
uate the presence of differences between the groups, the
Student's paried t- test, the Wilcoxon's signed-rank test or
the McNemar's test will be used according to the variable's
characteristics. Linear multiple regression will be used
with the purpose of comparing the results of the treat-
ments. The analysis will be performed by the intention-to-
treat approach. A p value under 0.05 will be considered as
statistically significant.
The primary endpoint for the analysis will be the change
in the value of HOMA index, fasting glucose and post-
charge glucose plasma levels. The secondary endpoint for
the analysis will include the changes in serum insulin, lep-
tin, adiponectin, resistin, CRP, IL-6, tPA/PAI-1 ratio, Oxi-
dized/Reduced glutathione ratio, malonaldehyde and 8-
isoprostanes.
Treatment safety will be evaluated by the clinical history
review and the statistics of the reported adverse events.
Safety committee and events assignation committee
A safety and events assignation committee will be created,
according to the Harmonized Tripartite Guidelines of the
International Conference of Harmonization for Good
Clinical Practice.
Ethical aspects
The clinical trial will be conducted according to the Hel-
sinki's Declaration, the Good Clinical Practice Guidelines
and the Colombian legislation (Resolution 8430/93 of
the Ministery of Health). The patient will provide written
informed consent in a form designed for such purpose.
The information generated by the study will be confiden-
tial and strictly limited to the purposes stipulated in the
protocol. The patient may refuse to continue participating
in the study at any moment after providing his/her con-
sent. The study has been approved by FVC ethics commit-
tee. All assessments will be performed by trained staff. The
blood samples will be collected in aseptic conditions by
an expert bacteriologist.
Study timeline
The study will last 36 months. The initiation will be
defined by the financial approval from the sponsor(Figure
3.).
Abbrebiations
(ACE) Angiotensin Converting Enzyme
(ACEIs) Angiotensin Converting Enzyme Inhibitors
title Figure 3
title. Study Timeline.Trials 2006, 7:28 http://www.trialsjournal.com/content/7/1/28
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(ADA) American Association of Diabetes
(AII)Angiotensin II
(AT1) Angiotensin II Type 1 Receptor
(AT2) Angiotensin II Type 2 Receptor
(BMI) Body Mass Index
(CRF) Case Report Form
(CRP) C-reactive Protein
(CVD) Cardiovascular Diseases
(DBP) Diastolic Blood Pressure
(DM2) Type-2 Diabetes Mellitus
(eNOS) Endothelial Nitric Oxide Synthase
(FAS) Fatty Acid Synthase
(FCV)Fundacion Cardiovascular de Colombia
(FFA) Free Fatty Acids
(FMD) Flow-Mediated Dilation
(GDPH) Glycerol-2 Dehydrogenate Phosphate
(HOMA) The Homeostasis Model Assessment
(IFG) Impaired Fasting Glucose
(IGT) Impaired Glucose Tolerance
(IL-6) Interleukine 6
(IRS-1 and IRS-2) Insulin Receptor Substrate Type 1 and
2
(MBP) Mean Blood Pressure
(MMP-2) Matrix Metalloproteinase-2
(NADPH)  Nicotinamide Adenine Dinucleotide Phos-
phate Hydrogen
(NO) Nitric Oxide
(OGTT) Oral Glucose Tolerance Test
(PAI-1) Plasminogen Activator Inhibitor-1
(PKC) Proteinkinase C
(PPARs) Peroxisome Proliferator-Activated Receptors
(RAS) Renin-Angiotensin-Aldosterone System
(ROS) Reactive Oxygen Species
(SBP) Systolic Blood Pressure
(SD) Standard Deviation
(TLC) Therapeutic Life-Style Change Program
(TNF-α) Tumor Necrosis factor alpha
(tPA) Tisular Plasminogen Activator
(UPC-2) Uncoupling Protein 2
(W/H-R) Waist-Hip Relation
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